Indian Journal of Cancer Publication fee - ResearchHelpDesk - Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of oncological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India. Its international repute is recognized by its indexing with most bibliographic databases including MEDLINE, Index Medicus, EMBASE and Biological Abstracts. The journal is the official publication of the Indian Cancer Society. The readership has expanded beyond the boundaries of the country. Apart from the journal's own website, the internet issue of the journal has been made available in collaboration with Bioline International, Canada. The journal's content from www.bioline.org.br/cn attracts more than 5000 visitors per month, from all over the world. The journal utilizes the most advanced tools for its management including an electronic system for manuscript submission and review. The journal provides immediate free access to all the published articles. The journal does not charge the authors for submission, processing or publication of the articles. Abstracting and Indexing Information The journal is registered with the following abstracting partners: Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TdNet, and Wanfang Data.

Background and AimPsycho-oncology is a cross-disciplinary and collaborative sub-specialty of oncology that focuses on the psychological, behavioral, ethical, and social aspects of cancer in clinical settings. The aim of this bibliometric study was to analyze and characterize the research productivity and trends in psycho-oncology between 1980 and 2021.MethodologyIn May 2022, the Scopus® database was searched for psycho-oncology-related publications using predetermined search keywords with specific restrictions. Lotka’s law was applied to check the authors’ productivity, while Bradford’s law was used to assess the core journals in this field. The data was analyzed for different bibliometric indicators in the Biblioshiny package, an RStudio tool for bibliometric analysis.ResultsThe initial search resulted in a total of 2,906 publications. Of which, 1,832 publications were included in the final analysis, published between 1980 and 2021. The analyzed publications were written by 7,363 authors from 74 countries and published in 490 journals. There has been a significant increase in psycho-oncology-related publications after 2010. The most productive year was 2021 (n = 365). The annual scientific growth rate was found to be 13.9%. The most relevant leading author in terms of publications was Luigi Grassi from the University of Ferrara, Italy (n = 42). Lotka’s law found that the number of authors declined as the number of papers written increased. The core journals were Psycho-Oncology, Supportive Care in Cancer, and Journal of Psychosocial Oncology. The most frequently used author’s keywords other than searching keywords were cancer, oncology, quality of life, depression, and anxiety. Recent psycho-oncology-related topics included mental health, COVID-19 infection in humans, people, pandemic, and tumor. The University of Sydney was the top-ranked institution. The leading country in terms of publications, citations, corresponding author country, and international collaboration was the United States of America (United States). The United States had the strongest collaboration with Australia and Canada.ConclusionThe research hotspots include mental health conditions and interventions in cancer patients. We identified international collaboration and research expenditure to be strongly associated with psycho-oncology research productivity. Researchers’ collaboration, which is visible among developed countries, should be extended to low-income countries in order to expand psycho-oncology-related research and understanding.

Background: Extracting inclusion and exclusion criteria in a structured, automated fashion remains a challenge to developing better search functionalities or automating systematic reviews of randomized controlled trials in oncology. The question “Did this trial enroll patients with localized disease, metastatic disease, or both?†could be used to narrow down the number of potentially relevant trials when conducting a search. Dataset collection: 600 randomized controlled trials from high-impact medical journals were classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. The dataset was randomly split into a training/validation and a test set of 500 and 100 trials respectively. However, the sets could be merged to allow for different splits. Data properties: Each trial is a row in the csv file. For each trial there is a doi, a publication date, a title, an abstract, the abstract sections (introduction, methods, results, conclus..., Randomized controlled oncology trials from seven major journals (British Medical Journal, JAMA, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology, New England Journal of Medicine) published between 2005 and 2023 were randomly sampled and annotated with the labels “LOCAL†, “METASTATIC†, both or none. Trials that allowed for the inclusion of patients with localized disease received the label “LOCAL†. Trials that allowed for the inclusion of patients with metastatic disease received the label “METASTATIC†. Trials that allowed for the inclusion of patients with either localized or metastatic disease received bot labels. Screening trials that enrolled patients without known cancer or trials of interventions to prevent cancer were assigned no label. Trials of tumor entities where the distinction between localized and metastatic disease is usually not made (e.g., hematologic malignancies) were skipped. Annotation was based on the title and abstract. If those were inconclusiv..., , # Randomized controlled oncology trials with tumor stage inclusion criteria

https://doi.org/10.5061/dryad.g4f4qrfzn

600 randomized controlled oncology trials from high-impact medical journals (British Medical Journal, JAMA, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology, New England Journal of Medicine) published between 2005 and 2023**Â **were randomly sampled and classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. The dataset was randomly split into a training/validation and a test set of 500 and 100 trials respectively. However, the sets could be merged to allow for different splits.

Description of the data and file structure

Each trial is a row in the csv file. For each trial there are the follwing columns:

• doi:Â Digital Object Identifier of the trial
• date: Publication data according to PubMed
• title: Title of the trial according to PubMed
• ab...

Indian Journal of Cancer FAQ - ResearchHelpDesk - Indian Journal of Cancer (ISSN 0019-509X), the show window of the progress of oncological sciences in India, was established in 1963. Indian Journal of Cancer is the first and only periodical serving the needs of all the specialties of oncology in India. Its international repute is recognized by its indexing with most bibliographic databases including MEDLINE, Index Medicus, EMBASE and Biological Abstracts. The journal is the official publication of the Indian Cancer Society. The readership has expanded beyond the boundaries of the country. Apart from the journal's own website, the internet issue of the journal has been made available in collaboration with Bioline International, Canada. The journal's content from www.bioline.org.br/cn attracts more than 5000 visitors per month, from all over the world. The journal utilizes the most advanced tools for its management including an electronic system for manuscript submission and review. The journal provides immediate free access to all the published articles. The journal does not charge the authors for submission, processing or publication of the articles. Abstracting and Indexing Information The journal is registered with the following abstracting partners: Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, National Science Library, ProQuest, TdNet, and Wanfang Data.

Dataset, Supplementary file. Visit https://dataone.org/datasets/sha256%3A1881f5eb2e39da93fe49af3172b577ff4aa2fb66903c03b903e55df08176c336 for complete metadata about this dataset.

Online journal and database devoted to genes, cytogenetics, and clinical entities in cancer, and cancer-prone diseases. Its aim is to cover the entire field under study and it presents concise and updated reviews (cards) or longer texts (deep insights) concerning topics in cancer research and genomics.

Dataset GSE45827 on breast cancer gene expression from CuMiDa

• 6 classes
• 54676 genes
• 151 samples

About

Here we present the Curated Microarray Database (CuMiDa), a repository containing 78 handpicked cancer microarray datasets, extensively curated from 30.000 studies from the Gene Expression Omnibus (GEO), solely for machine learning. The aim of CuMiDa is to offer homogeneous and state-of-the-art biological preprocessing of these datasets, together with numerous 3-fold cross validation benchmark results to propel machine learning studies focused on cancer research. The database make available various download options to be employed by other programs, as well for PCA and t-SNE results. CuMiDa stands different from existing databases for offering newer datasets, manually and carefully curated, from samples quality, unwanted probes, background correction and normalization, to create a more reliable source of data for computational research.

http://sbcb.inf.ufrgs.br/cumida

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F4372803%2Fa5700cd725b4eb18ae791b2e99868c01%2Fworkflowcumida.png?generation=1580134947371830&alt=media" alt="">

References

• Feltes, B.C.; Chandelier, E.B.; Grisci, B.I.; Dorn, M. (2019) CuMiDa: An Extensively Curated Microarray Database for Benchmarking and Testing of Machine Learning Approaches in Cancer Research. Journal of Computational Biology, 26 (4), 376-386. [https://doi.org/10.1089/cmb.2018.0238]

• Grisci, B. I., Feltes, B. C., & Dorn, M. (2019). Neuroevolution as a tool for microarray gene expression pattern identification in cancer research. Journal of biomedical informatics, 89, 122-133. [https://doi.org/10.1016/j.jbi.2018.11.013]

Inspiration

• How to deal with class imbalance for classification?
• How to identify the most important genes for the classification of each cancer subtype?
• Is it possible to discover subtypes?
• How to beat the classification and clustering benchmarks for this dataset listed on the CuMiDa website?

Search strategy. (DOCX)

Neocryptolepine is a natural alkaloid isolated from the African climbing plant Paeonia lactiflora, belonging to the indole quinoline alkaloid class. This compound has become a natural precursor widely studied by medicinal chemists due to its diverse biological activities, especially its potential applications in anti-tumor, anti-inflammatory, anti malaria and other fields. As a natural product with multiple biological activities,Neocryptolepine has great potential in cancer treatment research. Through in-depth research and development of the Neocryptolepine, it may provide new treatment options for cancer patients in the future.Cancer, as a global health challenge, has long plagued the medical community and patients. It is a disease caused by the unlimited proliferation, invasion, and metastasis of abnormal cells, which can affect any part of the human body. With the change of lifestyle, the aggravation of environmental pollution and the trend of aging population, the incidence rate of cancer has increased year by year and has become the second leading cause of death in the world. Despite its enormous potential in cancer treatment, the diversity, mechanisms, and unknown targets of action make it extremely challenging to obtain Neocryptolepine anti-cancer pathways from it. In addition, it is difficult to search for systematic information on anti-cancer Neocryptolepine from a large amount of information such as the internet. Neocryptolepine derivatives, as a natural compound, have shown great potential and diversity in cancer treatment. Despite facing challenges in screening and utilization, they remain important resources for drug development.In order to construct the NDADS database, authoritative literature search websites such as Pubmed and Google Scholar were used to systematically collect key information on the generic name, anti-tumor activity, cancer type, mechanism of action, and targets of Neocryptolepine and its derivatives using keywords such as Neocryptolepine, Cancer, and Target. On this basis, all data were integrated and included in the data of 85 Neocryptolepine derivatives in the laboratory, ultimately forming a database containing information on 203 anti-tumor compounds derived from Neocryptolepine derivatives. In order to integrate and evaluate numerous research resources and results, the Neocryptolepine derivatives anti-tumor database can provide rich retrieval and analysis tools, such as cross database retrieval, citation retrieval, journal retrieval, etc., enabling users to easily search for anti-tumor related information of Neocryptolepine derivatives. Supplement the current inclusion status, covering the names, structures, molecular weights, activities, functions, cancer types, cancer cells, targets/signaling pathways, references, and corresponding website sources of various compounds. This interface supports the query function for the content of the Neocryptolepine derivatives mentioned above. Therefore, the anti-tumor database of the Neocryptolepine derivatives will help to study the potential of Neocryptolepine derivatives in the treatment of cancer from multiple aspects such as activity, structure, method of action, and target, assisting in cancer treatment and improving cancer survival rate.

This spreadsheet contains the exported results from a dumb search on the Altmetric Explorer for the term "mastectomy" on academic articles mentioned [online] any time. It contains data from 180 articles and 79 journals. The search was done on 14 May 2013 around 21:20hrs BST. This spreadsheet was shared online by Ernesto Priego (City University London). The Altmetric Explorer can be found at http://www.altmetric.com This work is licensed under a Creative Commons Attribution 3.0 Unported License.

Enhancing the transparency in reporting the synthesis of qualitative research [ENTREQ].

Factors associated with overall survival in liver cancer patients.

Study characteristics on RCTs done to evaluate the comparative impact of integrated palliative care vs. standard care on the quality of life in cancer patients.

ContextPrior research has faulted the US News and World Report hospital specialty rankings for excessive reliance on reputation, a subjective measure of a hospital's performance.ObjectiveTo determine whether and to what extent reputation correlates with objective measures of research productivity among cancer hospitals.DesignA retrospective observational study.SettingAutomated search of NIH Reporter, BioEntrez, BioMedline and Clinicaltrials.gov databases.ParticipantsThe 50 highest ranked cancer hospitals in 2013's US News and World Report Rankings.ExposureWe ascertained the number of NCI funded grants, and the cumulative funds received by each cancer center. Additionally, we identified the number of phase I, phase II, and phase III studies published and indexed in MEDLINE, and registered at clinicaltrials.gov. All counts were over the preceding 5 years. For published articles, we summed the impact factor of the journals in which they appeared. Trials were attributed to centers on the basis of the affiliation of the lead author or study principal investigator.Main OutcomeCorrelation coefficients from simple and multiple linear regressions for measures of research productivity and a center's reputation.ResultsAll measures of research productivity demonstrated robust correlation with reputation (mean r-squared  = 0.65, median r-squared = 0.68, minimum r-squared = .41, maximum r-squared = 0.80). A multivariable model showed that 93% of the variation in reputation is explained by objective measures.ConclusionContrary to prior criticism, the majority of reputation, used in US News and World Rankings, can be explained by objective measures of research productivity among cancer hospitals.

Backgroundradiotherapy is one of the major treatments for lung cancer and has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer radiotherapy.MethodOn August 31, 2022, the authors identified 9868 articles on lung cancer radiotherapy by the Web of Science (Science Citation Indexing Expanded database) and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top-papers) as well as top-journals on lung cancer radiotherapy. After that, the authors analyzed the recent research hotspots based on the latest publications in top-journals.ResultsThese 9868 papers were cited a total of 268,068 times. “Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer” published in 2017 by Antonia et al.was the most cited article (2110 citations). Among the journals, New England Journal of Medicine was most influential. Moreover, J. Clin. Oncol. and Int. J. Radiat. Oncol. Biol. Phys. was both influential and productive. Corresponding authors represented the USA (2610 articles) and China mainland (2060 articles) took part in most publications and articles with corresponding authors from Netherlands were most cited (46.12 citations per paper). Chemoradiotherapy was the hottest research area, and stereotactic body radiotherapy has become a research hotspot since 2006. Radiotherapy plus immunotherapy has been highly focused since 2019.ConclusionsThis bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on 9868 relevant articles, and further suggests future research directions. The researchers can benefit in selecting journals and in finding potential collaborators. This study can help researchers gain a comprehensive picture of the research landscape, historical development, and recent hotspots in lung cancer radiotherapy and can provide inspiration for future research.

Delay between same site cancer records in source and comparator database.

BackgroundColorectal cancer (CRC) is one of the most commonly diagnosed advanced-stage malignancies worldwide and places a substantial burden on both the economic and social development of numerous countries.ObjectiveThis manuscript aims to synthesize the existing evidence and explore potential avenues for future scholarly research on ctDNA in CRC.MethodsBibliometric analyses were performed using the bibliometrix package in R, along with CiteSpace and VOSviewer software. The search was restricted to publications up to 31 March 2024, using the following terms: (“ctDNA” OR “circulating tumor DNA”) AND (“colorectal cancer” OR “colorectal tumor”) from the Web of Science Core Collection (WoSCC) database.ResultsUltimately, we identified 1,310 documents published in 353 journals authored by 7,683 researchers from 2,417 institutions across 66 countries. The USA was the most productive country. The Journal of Clinical Oncology was the most prolific, publishing 111 articles with 3,396 citations. The top five keywords were “colorectal cancer,” “circulating tumor DNA,” “acquired resistance,” “cell-free DNA,” and “plasma.” The top five cluster labels for references were “advanced cancer,” “metastatic colorectal cancer,” “liquid biopsy,” “colorectal cancer,” and “human colorectal cancer xenograft.”ConclusionsThe collaborative networks are primarily composed of highly productive authors, prestigious institutions, and leading countries. Additionally, the advancement of detection technologies, the development of standardized protocols, the exploration of circulating tumor DNA (ctDNA) dynamics in CRC, and the implementation of large-scale clinical trials for ctDNA-guided precision therapy in CRC are expected to become major research priorities in the future.

BackgroundEsophageal cancer is currently a worldwide health problem. Esophageal squamous cell carcinoma (ESCC) is the most common pathological type of esophageal cancer, and its treatment methods and therapeutic effects are relatively limited, so it also requires the unremitting efforts of basic and clinical researchers to overcome difficulties. Bibliometric analysis can help sort out global research trends and hotspots, but no bibliometric analysis of ESCC has been reported. Therefore, we performed this study to analyze the global trends and potential hotspots of ESCC to indicate future research directions.MethodsThe articles related to ESCC research were collected from the WoS Core Collection SCI-EXPANDED database from 2012 to 2022. The article information was analyzed by BiblioShiny and VOSviewer. Results were presented as bar and network visualization to describe the current trend of ESCC research. This was a retrospective study evaluating data that is publicly available online and at libraries and institutional review board approval, as such, was not demanded.ResultsThe global publication trend illustrated a strong growth in the ESCC research field (annual growth rate of 11.4%) and the citation trend increased from an average of 2.98 citations per article per year in 2012 to an average of 3.84 citations per article per year in 2019. With the corresponding author’s country, China contributed the largest number (5,063 articles). The scholars from China and USA had the most collaboration (427 times). China had the largest number of institutions conducting ESCC research. Oncotarget, Oncology Letters, and Annals of Surgical Oncology published the most articles, while Cancer Research, International Journal of Cancer, and Journal of Clinical Oncology had the most local citations. Furthermore, the clinical research hotspots involved in the treatment of ESCC and the basic research hotspots involved in tumor malignant phenotype have received the most attention in recent years.ConclusionOur study demonstrated that the research of ESCC has developed rapidly in recent years, and the academic institutions in China have played a decisive role in this field. The global research purpose is to find effective therapies against ESCC, so some emerging hotspots related to ESCC treatment, such as endoscopic therapy, chemoradiotherapy, immunotherapy, tumor microenvironment, and the epithelial-mesenchymal transition will receive more attention and develop rapidly in the future.

We have compiled a database of publications on skin cancer preventative modalities. The purpose of the dataset is to ease and guide research on developing new treatments for skin cancer prevention. By sharing the database, we hope to reduce redundancy when evaluating photoprotective modalities and allow researchers to build upon experience already available.The database was created by Celina Pihl, Catharina Margrethe Lerche, Merete Haedersdal, Peter Bjerring, and Flemming Andersen. All creators are a member of the Danish Research Center for Skin Cancer.The database will be updated yearly.An accompanying article (A Curated and Updated Database of Pharmacological Skin Cancer Preventative Modalities) has been published in The Journal of Investigative Dermatology.

ObjectiveThis study evaluated the risk of cancer among patients with iron deficiency anemia (IDA) by using a nationwide population-based data set.MethodPatients newly diagnosed with IDA and without antecedent cancer between 2000 and 2010 were recruited from the Taiwan National Health Insurance Research Database. The standardized incidence ratios (SIRs) of cancer types among patients with IDA were calculated.ResultsPatients with IDA exhibited an increased overall cancer risk (SIR: 2.15). Subgroup analysis showed that patients of both sexes and in all age groups had an increased SIR. After we excluded patients diagnosed with cancer within the first and first 5 years of IDA diagnosis, the SIRs remained significantly elevated at 1.43 and 1.30, respectively. In addition, the risks of pancreatic (SIR: 2.31), kidney (SIR: 2.23), liver (SIR: 1.94), and bladder cancers (SIR: 1.74) remained significantly increased after exclusion of patients diagnosed with cancer within 5 years after IDA diagnosis.ConclusionThe overall cancer risk was significantly elevated among patients with IDA. After we excluded patients diagnosed with IDA and cancer within 1 and 5 years, the SIRs remained significantly elevated compared with those of the general population. The increased risk of cancer was not confined to gastrointestinal cancer when the SIRs of pancreatic, kidney, liver, and bladder cancers significantly increased after exclusion of patients diagnosed with IDA and cancer within the first 5 years. This finding may be caused by immune activities altered by IDA. Further study is necessary to determine the association between IDA and cancer risk.